Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
|ClinicalTrials.gov Identifier: NCT01570855|
Recruitment Status : Completed
First Posted : April 4, 2012
Last Update Posted : April 27, 2016
|Condition or disease|
The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory.
The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.
|Study Type :||Observational|
|Actual Enrollment :||45 participants|
|Official Title:||Chemotherapy Resistance and Sensitivity Testing in Lung Tumors|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||December 2015|
- Tumor size [ Time Frame: 3 months ]
Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start.
Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01570855
|United States, West Virginia|
|Cabell Huntington Hospital|
|Huntington, West Virginia, United States, 25701|
|Principal Investigator:||Pier P. Claudio, M.D., Ph. D||Marshall University School of Medicine|